These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 16046901)

  • 1. Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers.
    Sierra C; de la Sierra A
    Curr Opin Nephrol Hypertens; 2005 Sep; 14(5):435-41. PubMed ID: 16046901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin receptor blockers in hypertension and cardiovascular diseases.
    de la Sierra A
    Cardiovasc Hematol Agents Med Chem; 2006 Jan; 4(1):67-73. PubMed ID: 16529551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular and metabolic effects of angiotensin II receptor blockers.
    Barra S; Vitagliano A; Cuomo V; Vitagliano G; Gaeta G
    Expert Opin Pharmacother; 2009 Feb; 10(2):173-89. PubMed ID: 19236192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease.
    Michel MC; Brunner HR; Foster C; Huo Y
    Pharmacol Ther; 2016 Aug; 164():1-81. PubMed ID: 27130806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.
    Thomas GN; Chan P; Tomlinson B
    Drugs Aging; 2006; 23(2):131-55. PubMed ID: 16536636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug Treatment of Hypertension: Focus on Vascular Health.
    Cameron AC; Lang NN; Touyz RM
    Drugs; 2016 Oct; 76(16):1529-1550. PubMed ID: 27667708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers.
    Verdecchia P; Gentile G; Angeli F; Reboldi G
    Ther Adv Cardiovasc Dis; 2012 Apr; 6(2):81-91. PubMed ID: 22528743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin receptor blockers: novel role in high-risk patients.
    Javed U; Deedwania PC
    Cardiol Clin; 2008 Nov; 26(4):507-26. PubMed ID: 18929228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin II receptor blockers in older patients.
    Weber MA
    Am J Geriatr Cardiol; 2004; 13(4):197-205; quiz 206-7. PubMed ID: 15269566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure.
    Meredith PA
    Curr Med Res Opin; 2007 Jul; 23(7):1693-705. PubMed ID: 17588300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II type I receptor blocker and endothelial function in humans: role of nitric oxide and oxidative stress.
    Higashi Y; Chayama K; Yoshizumi M
    Curr Med Chem Cardiovasc Hematol Agents; 2005 Apr; 3(2):133-48. PubMed ID: 15853700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of angiotensin II type 1 receptor blocker action in the regression of left ventricular hypertrophy.
    Kjeldsen SE; Strand A; Julius S; Okin PM
    J Clin Hypertens (Greenwich); 2006 Jul; 8(7):487-92. PubMed ID: 16849902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical Issues.
    Borghi C; ; Rossi F;
    High Blood Press Cardiovasc Prev; 2015 Dec; 22(4):429-44. PubMed ID: 26403596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal protection with angiotensin receptor blockers: where do we stand.
    Schmieder RE; Ruilope LM; Barnett AH
    J Nephrol; 2011; 24(5):569-80. PubMed ID: 21404225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
    Zeller A; Battegay E
    Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.